Response Genetics and Hitachi Provide Diagnostic Testing Services to Asia-Pacific

(RGI; Los Angeles, CA, USA) has entered into a collaboration agreement with Hitachi Chemical Co., Ltd. (Tokyo, Japan), a diagnostics manufacturer. Under the terms of this agreement, Hitachi Chemical will begin using RGI's techniques to extract genetic information from formalin-fixed paraffin-embedded (FFPE) tissue samples collected in Southeast Asia, Australia, and New Zealand. RGI will provide Hitachi Chemical with the technical information and assistance necessary to perform the testing services, and the two companies will divide the revenues.

Hitachi Chemical will introduce RGI to potential new customers in the region to expand the testing of FFPE clinical samples in Asia. The countries covered under this agreement include Japan, North Korea, South Korea, Taiwan, Mongolia, Pakistan, Bangladesh, Sri Lanka, Nepal, Singapore, Malaysia, Indonesia, Brunei, Thailand, Myanmar, Laos, Cambodia, Vietnam, and the Philippines.

"We are delighted to be partnering with the well-known diagnostics company Hitachi Chemical in three key markets, Southeast Asia, Australia, and New Zealand, said Kathleen Danenberg, president and CEO of Response Genetics. "This collaboration is part of our global strategy to provide diagnostic testing services to pharmaceutical companies conducting clinical studies worldwide.”

RGI develops pharmacogenomic cancer diagnostic tests based on technologies that enable extraction and analysis of genetic information from genes derived from tumor samples and stored as formalin-fixed and paraffin-embedded specimens.


Related Links:
Response Genetics
Hitachi Chemical